Related Experiment Video

Updated: May 4, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K

Why anti-Bcl-2 clinical trials fail: a solution

Y Harazono1, K Nakajima, A Raz

  • 1Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, USA.

Cancer Metastasis Reviews
|December 17, 2013
PubMed

Insights

Targeting the antiapoptotic protein galectin-3 (Gal-3) alongside B cell lymphoma-2 (Bcl-2) may improve cancer therapy efficacy. Failure to consider Gal-3 levels could explain past clinical trial failures for Bcl-2 targeted treatments.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cellular Biology

Background:

  • B cell lymphoma-2 (Bcl-2) family proteins regulate apoptosis and are key targets in cancer therapy.
  • Previous Bcl-2 targeting therapies have shown limited clinical success due to unknown reasons.
  • Galectin-3 (Gal-3), an oncogenic protein, also regulates apoptosis and possesses an anti-death motif similar to Bcl-2 family proteins.

Purpose of the Study:

  • To review the roles of Gal-3 and Bcl-2 in apoptosis regulation.
  • To propose a novel combination therapy targeting both Gal-3 and Bcl-2 for improved cancer treatment outcomes.
  • To highlight the importance of considering Gal-3 levels in the context of Bcl-2 targeted cancer therapies.

Main Methods:

  • Literature review on the functions of Bcl-2 family proteins and galectin-3 in cancer.
  • Analysis of the mechanisms by which Gal-3 inhibits apoptosis and confers drug resistance.
  • Proposal of a combination therapeutic strategy involving Gal-3 and Bcl-2 targeting agents.

Main Results:

  • Gal-3 is identified as a crucial regulator of apoptosis, acting via phosphorylation, translocation, and survival pathway modulation.
  • Gal-3's NWGR anti-death motif suggests a functional link to the Bcl-2 family.
  • Gal-3 is proposed as a critical factor influencing the efficacy of Bcl-2 targeted cancer therapies.

Conclusions:

  • Combination therapy targeting both Gal-3 and Bcl-2 holds promise for enhancing anticancer drug efficacy.
  • Future clinical trials should investigate Gal-3 as a therapeutic target in conjunction with Bcl-2 inhibitors.
  • Ignoring Gal-3's role in apoptosis may lead to the failure of current and future cancer treatment strategies.

More Related Videos

Examining BCL-2 Family Function with Large Unilamellar Vesicles08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

7.4K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K